Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAR001 in Patients With Elevated Triglycerides and Remnant Cholesterol
NCT07028749Phase 2Recruiting
- Sponsor
- Marea Therapeutics
- Start
- Jun 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of MAR001 in hypertriglyceridemia, sponsored by Marea Therapeutics. Started Jun 2025; status: recruiting.
02
Drugs
MAR001
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT07028749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028749.